anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Stimulation-based language mapping approaches that are used pre- and intraoperatively employ predominantly overt language tasks requiring sufficient language production abilities. Yet, these production-based setups are often not feasible in brain tumor patients with severe expressive aphasia. This pilot study evaluated the feasibility and reliability of a newly developed language comprehension task with preoperative navigated transcranial magnetic stimulation (nTMS).
METHODS: Fifteen healthy subjects and six brain tumor patients with severe expressive aphasia unable to perform classic overt naming tasks underwent preoperative nTMS language mapping based on an auditory single-word Comprehension TAsk for Perioperative mapping (CompreTAP). Comprehension was probed by button-press responses to auditory stimuli, hence not requiring overt language responses. Positive comprehension areas were identified when stimulation elicited an incorrect or delayed button press. Error categories, case-wise cortical error rate distribution and inter-rater reliability between two experienced specialists were examined.
RESULTS: Overall, the new setup showed to be feasible. Comprehension-disruptions induced by nTMS manifested in no responses, delayed or hesitant responses, searching behavior or selection of wrong target items across all patients and controls and could be performed even in patients with severe expressive aphasia. The analysis agreement between both specialists was substantial for classifying comprehension-positive and -negative sites. Extensive left-hemispheric individual cortical comprehension sites were identified for all patients. Apart from one case presenting with transient worsening of aphasic symptoms, pre-existing language deficits did not aggravate if results were used for subsequent surgical planning.
CONCLUSION: Employing this new comprehension-based nTMS setup allowed to identify language relevant cortical sites in all healthy subjects and severely aphasic patients who were thus far precluded from classic production-based mapping. This pilot study, moreover, provides first indications that the CompreTAP mapping results may support the preservation of residual language function if used for subsequent surgical planning.
A 46-year-old Japanese man was referred to our hospital because of a marked increase in his eosinophil count (22,870/μL) and elevated liver enzyme levels. Computed tomography (CT) showed thrombi measuring approximately 8 cm in both femoral veins. A liver biopsy revealed eosinophilic infiltration, hepatocyte necrosis, fibrosis, and multiple thrombi. We suspected acute liver injury and deep vein thrombosis associated with hypereosinophilic syndrome and initiated steroids and heparin treatment. Four days after starting treatment, the patient experienced sudden chest pain and cardiopulmonary arrest. CT revealed bilateral pulmonary artery thrombosis, and despite administration of a tissue plasminogen activator, the patient died.
SBRT treatment will commence within 7 days post randomisation and will be administered as detailed in the SOPRANO Radiotherapy Planning and Delivery Guidelines document. Doses will vary between 3 fractions over 5 days to 8 fractions over 19 days depending on the location of the lesions being treated.
Current non-invasive neuromodulatory approaches like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have proven efficacious for inducing transient plastic changes in the human cortex. However, these technologies have poor spatial resolution, suffer from a depth focality tradeoff and experience significant attenuation at depth. Thus, they cannot effectively target neural tissue below the surface of the cortex. Transcranial focused ultrasound (tFUS) is a new and very promising non-surgical low-energy technique for inducing transient plasticity with high spatial resolution, adjustable focus and low tissue attenuation. tFUS has been used safely and effectively for neural stimulation in mouse, rabbit and monkey and my research has shown tFUS to also be a safe and effective method of transient cortical stimulation in humans. Having demonstrated its efficacy in humans for cortical stimulation, the next step is to take advantage of tFUS' high spatial resolution and deep focal lengths to stimulate sub-cortical neural structures. Currently, the only way to stimulate sub-cortical structures involves expensive and risky surgery. It is the purpose of this proposal to test tFUS for sub-cortical stimulation. The ability to individually stimulate small neural structures deep to the cortex without invasive surgery would have broad application in basic neuroscience for the investigation of brain structure and function as well as for the potential diagnosis and therapy of many neurological and psychiatric diseases.
PURPOSE:To obtain a skin detergent, having foaming functions in addition to makeup removing functions and capable of providing a refreshing feeling of washing the bare skin by combining a polyoxyalkylene-modified methylpolysiloxane with a specific anionic surfactant. CONSTITUTION:This skin detergent contains a polyoxyalkylene-modified methylpolysiloxane expressed by the formula {R is H or a 1-5C alkyl; (x) and (y) each is 0-30 and [(x)+(y)] is 5-60; (m) is 0-50; (n) is 1-50} and an anionic surfactant except a fatty acid soap. The polyoxyalkylene-modified methylpolysiloxane is preferably contained in an amount of 15-18wt.% expressed in terms of weight ratio of the polyoxyalkylene to the molecular weight of the polyoxyalkylene-modified methylpolysiloxane. For example, an alpha- acylsulfonate, an alkylsulfonate, an alkyl sulfate and an alkylhydroxy ether carboxylate are cited as the anionic surfactant. The blending ratio of the compound expressed by the formula to the anionic surfactant is preferably within the range of (1:1) to (1:8) expressed in terms of weight ratio. The detergent can be foamed by well removing a makeup cosmetic and simultaneously adding water thereto.
A set of healing abutments includes a first healing abutment and a second healing abutment. The first healing abutment has an upper surface with a first code thereon. The first code is associated with a size of the first healing abutment. The second healing abutment has an upper surface with a second code thereon. The second code is associated with a size of the second healing abutment. The first healing abutment and the second healing abutment have the same size. The first code is different from the second code.
A poliomyelitis virus vaccine comprises a sterile aqueous fluid containing poliomyelitis virus, e.g. Types 1, 2 and/or 3, which has been killed partly by the action of betapropiolactone which is substantially free from its decomposition products, and partly by treatment with ultraviolet light, the vaccine being free from living virus and capable of immunizing mammals against infection by living poliomyelitis virus.  The vaccine may be produced by subjecting aqueous fluid containing living virus to the actions of ultraviolet irradiation and betapropiolactone such that one of said actions is sufficient to kill a major proportion of the virus and the other of said actions being sufficient to kill all the residual live virus, neither action in the extent employed being alone capable of killing all the virus present.  Fluids containing Types 1, 2 or 3 virus may be thus treated and subsequently mixed to produce a trivalent vaccine.  The aqueous fluid containing living virus may be exposed to ultraviolet light to reduce the infectivity titre to a low value, and then to the action of betapropiolactone in a concentration of between 0.0002 and 0.0010 grams per millilitre of fluid.  A thin film of an aqueous fluid containing the living virus may be exposed to ultraviolet light at about 12,500 to 32,000 microwatts per square centimetre having a major proportion of energy at a wavelength of 2000 to 3000 Angstrom units for 0.5 to 2 seconds and to the action of betapropiolactone in a concentration of between 0.0002 and 0.0010 grams per millilitre, for a length of time sufficient to kill all the living virus present.  A film of the aqueous fluid of not greater than 100 microns thickness, which may have a pH of between 5 and 9 and containing from 0.0002 to 0.0010 grams per millilitre of betapropiolactone may be exposed to about 25,000 microwatts per square centimetre of ultraviolet light at a wavelength of 2537 Angstrom units for 0.5 to 2 seconds, and then held, e.g. at 20 DEG to 40 DEG  C., for a time sufficient to enable the betapropiolactone still in the fluid to kill all the remaining virus.  The vaccines, which may be diluted with suitable diluents such as sterile Hank's solution, sterile saline solution and sterile distilled water, may be administered subcutaneously, intradermally, or intramuscularly, and may contain germicidal and/or stabilizing agents, e.g. benzethonium chloride.  Specification 655,198 and U.S.A. Specification 2,725,482 are referred to.
Methods, devices and compositions for fusing adjacent vertebrae, and otherwise localizing bone growth, are provided. In one form of the invention, a method for fusing adjacent vertebrae includes preparing a disc space for receipt of an intervertebral disc implant in an intervertebral disc space between adjacent vertebrae, inserting the implant into the intervertebral disc space and providing an osteoinductive composition that includes an osteoinductive factor in a pharmaceutically acceptable carrier. The carrier is advantageously substantially impermeable to efflux of the osteoinductive factor and is released as the carrier is resorbed or biodegraded. Preferred carriers include a hardened, resorbable carrier, such as a calcium phosphate cement that retains at least about 50% of the osteoinductive factors greater than about 2 days. Preferred osteoinductive factors are growth factors and include bone morphogenctic proteins and LIM mineralization proteins. In alternative forms of the invention, the method may be performed without utilization of a load-bearing spinal implant by disposing the osteoinductive composition in the disc space. The method is advantageously performed on lumbar vertebrae by a posterior approach. Intervertebral fusion devices and methods for their preparation are also provided.
PURPOSE:To prevent separation of a reaction system and violent foaming and obtain the titled ester in good yield, by stirring sucrose and a lower alcohol ester of a fatty acid in the presence of a soap and a sucrose ester of a fatty acid at a specific linear velocity and subjecting the resultant product to molecular distillation. CONSTITUTION:A lower alcohol ester of a fatty acid, e.g. methyl stearate, is added to sucrose in one stage, and reacted in the presence of an alkali catalyst, e.g. K2CO3, and further a soap which is an alkali salt of a fatty acid, e.g. sodium stearate, and/or sucrose ester of a fatty acid, e.g. sucrose oleate, as the third component within preferably 2.0-20m/sec linear velocity range while stirring. An acid is then added to the resultant product to reduce the pH to <=6 and convert the coexisting soap into the fatty acid, which is removed. The unreacted lower alcohol ester of the fatty acid is then removed by molecular distillation to afford the aimed ester having >=3 average substitution degree.
We aimed to determine the efficacy of the various available oral, topical, and procedural treatment options for hair loss in individuals with androgenic alopecia. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review of the National Library of Medicine was performed. Overall, 141 unique studies met our inclusion criteria. We demonstrate that many over the counter (e.g. topical minoxidil, supplements, low-level light treatment), prescription (e.g. oral minoxidil, finasteride, dutasteride), and procedural (e.g. platelet-rich plasma, fractionated lasers, hair transplantation) treatments successfully promote hair growth, highlighting the superiority of a multifaceted and individualized approach to management.
Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
Androgenic alopecia (AGA) is a common, progressive hair loss disorder affecting both sexes with significant negative impact on social and psychological well-being. The frequency and severity increases with age, and up to 80% of men, and 50% of women are affected by AGA over the course of their lives. While men are more frequently affected, the psychological impact is likely to be high for women where the social impact of hair loss is often devastating. Current medical therapies specifically approved by the US FDA are limited to minoxidil (for men and women) and finasteride (for men only) (Varothai), but variable responses and the need for indefinite use often result in patient fatigue and suboptimal compliance. Recently, there has been interest in treatments orientated to more biologically regenerative therapies, and consequently there have been numerous studies that have demonstrated successful use for platelet rich plasma (PRP) in treating AGA. PRP contains concentrated platelet cells derived from autologous whole blood that are believed to activate a cascade of growth factors when injected into an area of poor hair growth that stimulates hair growth. In this proposal we will examine whether PRP therapy provides similar or better hair growing capacity in women compared to the conventional topical application minoxidil.
BACKGROUND: Patients with a traumatic brachial plexus injury (BPI) have previously identified the need for improved patient education tools, emphasizing the importance of communicating outcome expectations, providing attention to the emotional aspects of the injury and the treatment of pain, and acknowledging the needs of caregivers. We created a journey guide, a BPI-specific educational tool, to address these deficiencies. In this study, we determined the acceptability of the journey guide through surveys of and semistructured interviews with patients with a BPI.
METHODS: The journey guide was created by a multidisciplinary team focusing on previously defined areas for the improvement of patient education and care delivery related to BPI. To assess the acceptability of the journey guide, we recruited 19 participants from the brachial plexus clinic of our institution and the United Brachial Plexus Network to complete a series of surveys and semistructured interviews. Participants completed surveys regarding their satisfaction with the journey guide, and we conducted semistructured interviews to assess patient BPI experiences and impressions of the journey guide and to seek feedback. Interview transcripts were qualitatively analyzed to determine common themes for improvement.
RESULTS: A total of 19 participants with a mean age of 44.7 years were included. The cohort was predominantly male (13 participants) and White (16 participants). The mean time since BPI was 12.9 years, ranging from 2.0 to 39.7 years. On a visual analog scale, satisfaction with the journey guide was given a mean score of 8.4; expected usefulness when a patient is first injured, 8.7; potential for continued use, 7.3; and the fit for the BPI community, 8.8. Qualitative analysis demonstrated a primarily positive view of the guide and identified 4 major themes: (1) visuals and quotes improve clarity and engagement, (2) the journey guide would be most useful immediately following an injury, (3) the journey guide is an effective organizational tool, and (4) it is difficult to orient patients toward future hardships.
CONCLUSIONS: The journey guide successfully filled a gap in the current care for BPI and was largely deemed acceptable by patients with a BPI. Specifically, participants found the journey guide to be a concise educational resource and an effective organizational tool. Participants also indicated that areas for improvement include the increased use of graphics and images and recognition of the greater BPI community with which patients can engage.
BACKGROUND: This study investigates the clinical efficacy and safety of percutaneous endoscopic nucleotomy combined with platelet-rich plasma (PRP) injection in treating lumbar disc herniation (LDH) in young and middle-aged adults.
METHODS: From April 2022 to September 2023, 60 patients diagnosed with LDH were randomly divided into two groups (n = 30/group). The observation group underwent percutaneous endoscopic nucleotomy combined with autologous PRP gel injection into the disc, while the control group underwent percutaneous endoscopic nucleotomy alone. Visual Analogue Scale (VAS) scores and Oswestry Disability Index (ODI) scores were recorded preoperatively and at three time points postoperatively: three days, three months, and six months. The modified Macnab criteria were employed to evaluate efficacy at the final follow-up. Additionally, MRI Pfirrmann grading of the operated disc segment and potential complications were assessed both preoperatively and at the final follow-up.
RESULTS: All patients were followed for a minimum of six months. VAS and ODI scores at all postoperative time points (three days, three months, and six months) exhibited significant differences compared to preoperative scores in both groups (P < 0.05). Notably, a significant difference was observed in VAS and ODI scores between the two groups at three days postoperatively (P < 0.05). Preoperative MRI Pfirrmann grading indicated no significant difference between groups (P = 0.669). However, at the final follow-up, the observation group demonstrated superior recovery compared to the control group (P = 0.013). The modified Macnab criteria revealed no significant difference in the rates of excellent and good outcomes between the observation group (96.67%) and the control group (93.33%) (P > 0.05). Furthermore, no patients experienced complications such as dural tears, nerve root injury, infection, or hematoma.
CONCLUSION: The combination of percutaneous endoscopic nucleotomy and PRP injection could be a safe and effective treatment for LDH in young and middle-aged adults to promote disc repair following endoscopic procedures.
Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
The present invention discloses a compound of a fluorinated carboxyl alkyl cyclodextrin ether kind, and a preparation method and a purpose thereof. The chemical structure general formula of the compound is disclosed in the specification. In the preparation method of the compound, the halogenated fluorinated alkyl carboxylic acid and parent body cyclodextrin are mixed in a solvent with the presence of base; acid is added, an obtained mixed liquid containing the fluorinated carboxyl alkyl cyclodextrin ether is mixed with a reactant, and then, the compound is obtained. The present invention has the advantages of simplicity, easy operation and control and low production cost and is favorable for popularization and application. When the compound is used as medicine dressing, the compound greatly improves the dissolvability of medicine in a solution and obviously enhances medicine stability. When the compound is used as a chiral auxiliary agent, the compound can be applied to the separation of chiral compounds in capillary electrophoresis, gas phase chromatographs, etc., and the compound has simple and convenient operation, high separating degree and low separating cost. Additionally, the compound can be used for preparing pesticide, organic waste, dye, coloring agents, photo color development coupling agents, perfume, essence or food additives, etc.
In a process for removing impurities from an extract containing material having anti-pernicious an mia activity, e.g. an extract of liver or prepared from micro-organisms, the extract is treated with nitrous acid.  The acidic impurities may be removed by means of an organic solvent, e.g. ether, chloroform, lower aliphatic esters, and butyl and amyl alcohols from the resulting solution, or alternatively by anion-exchange resins. Alternatively the active material may be extracted from the solution resulting from the nitrous acid treatment by rendering the latter neutral or alkaline and extracting with a suitable solvent.  Detailed examples are given.  Specifications 469,430 and 665,485 are referred to.
Purpose: In this study, we identified differentially expressed genes (DEGs) and signaling pathways to gain insight into the pathogenesis of acute lung injury (ALI). Methods: C57BL/6 mice were intravenously injected with lipopolysaccharide (LPS) to establish a sepsis-induced ALI model. Hematoxylin-eosin (H&E) and enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the model. Whole transcriptome sequencing was performed to identify the expression changes in lncRNAs, circRNAs, miRNAs and mRNAs in lung tissues. The crucial RNAs and the biological function of the target genes were confirmed and annotated based on bioinformatics analysis. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was employed to verify the expression levels of key lncRNAs, circRNAs, miRNAs and mRNAs in the lung tissues and human bronchoalveolar lavage (BALF). Results: A total of 3304 (1632 upregulated and 1672 downregulated) differentially expressed mRNAs, 794 (397 up and 397 down) differentially expressed lncRNAs, 89 (58 up and 31 down) differentially expressed circRNAs, and 14 (11 up and 3 down) differentially expressed miRNAs were identified between the control and LPS lung tissues. The lncRNA ceRNA subnetwork and circRNA ceRNA subnetwork were constructed based on the observed interaction and co-expression among the differentially expressed RNAs. An analysis of the protein-protein interaction (PPI) network and hub genes revealed crucial mRNAs for circRNA-Tcf20. The lncRNA-Snhg12, Edn1, Stat1, miR-212-3p and miR-223-3p were upregulated in sepsis ARDS patients. CircRNA-Tcf20, Col1a1, Col1a2 and Flt3 were significantly downregulated in sepsis ARDS patients. The biological function analysis indicated that these genes were enriched in the TNF signaling pathway, Necroptosis signaling pathway and the PI3K-Akt signaling pathway. Conclusions: Our findings suggest that circRNA-Tcf20, miR-212-3p, miR-223-3p, Col1a1, Col1a2 and Flt3 may be new regulatory factors that participate in the pathogenesis of sepsis-related acute lung injury. CircRNA-Tcf20, lncRNA-Snhg12 and all the other RNAs may be potential biomarkers for septic ALI/ARDS.
Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.